YaoTang Biological YOLT-101 has obtained approval from the National Medical Products Administration for clinical trials, used in the treatment of familial hypercholesterolemia.

On July 14, Yaotang Biology announced that the clinical trial application for YOLT-101 injection jointly applied by Yaotang Biology and Shenzhen Xellia Pharmaceuticals Co., Ltd. has been officially approved by the Drug Evaluation Center of the National Medical Products Administration. YOLT-101 is intended to be developed for the indication of heterozygous familial hypercholesterolemia.